...
首页> 外文期刊>International journal of laboratory hematology >Novel and rapid enumeration method of peripheral blood stem cells using automated hematology analyzer
【24h】

Novel and rapid enumeration method of peripheral blood stem cells using automated hematology analyzer

机译:使用自动血液分析仪的新型快速计数外周血干细胞的方法

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: The number of infused CD34+ cells is crucial to the success of peripheral blood stem cell transplantation (PBSCT). Here, we present, for the first time, a new method of enumerating hematopoietic progenitor cells (HPCs) for PBSCT. Method: This novel method is based on hemolysis and chemical staining, followed by flow cytometry-based optical detection, conducted using an automated hematology analyzer (XN series, Sysmex). CD34+ cells and HPCs were compared in 76 granulocyte colony-stimulating factor (G-CSF)-mobilized blood or apheresis samples taken from healthy donors (n = 18) or patients undergoing autologous PBSCT (n = 6). Results: There was a strong correlation between the numbers of HPCs and CD34+ cells (R2 = 0.958). The expected total number of HPCs in the final products, which was estimated from HPCs in pre-apheresis PB or mid-apheresis products, also correlated well with the total number of CD34+ cells in the final products. The change in HPCs in PB closely resembled that of CD34+ cells during mobilization. Experiments using immunomagnetic beads suggested that the majority of CD34+ cells existed in HPCs, and vice versa. Conclusion: Hematopoietic progenitor cells may serve as surrogates for CD34+ cells in PBSCT. However, further investigations are required to verify this.
机译:简介:注入的CD34 +细胞的数量对于外周血干细胞移植(PBSCT)的成功至关重要。在这里,我们首次提出了一种新的为PBSCT枚举造血祖细胞(HPC)的方法。方法:这种新方法基于溶血和化学染色,然后使用自动血液分析仪(XN系列,Sysmex)进行基于流式细胞仪的光学检测。在从健康供体(n = 18)或接受自体PBSCT(n = 6)的患者中采集的76粒粒细胞集落刺激因子(G-CSF)动员的血液或血液采血样本中比较了CD34 +细胞和HPC。结果:HPC和CD34 +细胞的数量之间有很强的相关性(R2 = 0.958)。最终产品中预期的HPC总数是根据前剥离前PB或中位数分离产品中的HPC估算得出的,也与最终产品中CD34 +细胞的总数有很好的相关性。 PB中HPC的变化与动员期间CD34 +细胞的变化非常相似。使用免疫磁珠的实验表明,大多数CD34 +细胞存在于HPC中,反之亦然。结论:造血祖细胞可作为PBSCT中CD34 +细胞的替代物。但是,需要进一步调查以验证这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号